INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
ApexOnco Front Page
Recent articles
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The Breakwater study hits on overall survival with "unprecedented" data.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
